ProChon and Savyon co-operate on bladder cancer kit:
This article was originally published in Clinica
Executive Summary
Rehovat, Israel-based ProChon Biotech and clinical diagnosis tools company Savyon Diagnostics last week struck a deal to develop and manufacture a genetic kit for the diagnosis of bladder cancer mutations. Under the agreement, Ashdod-based Savyon will assume responsibility for prototype kit development and manufacturing whilst ProChon, a discoverer and developer of fibroblast growth-factor based therapeutics, will be responsible for clinical development and will retain exclusive worldwide commercial rights.